Virios Therapeutics, Inc. (NASDAQ:VIRI – Get Free Report) shares fell 1.5% during trading on Thursday . The stock traded as low as $5.82 and last traded at $5.96. 52,000 shares traded hands during mid-day trading, a decline of 95% from the average session volume of 1,049,645 shares. The stock had previously closed at $6.05.
Virios Therapeutics Price Performance
The company has a market capitalization of $114.78 million, a price-to-earnings ratio of -22.07 and a beta of 1.58. The firm has a fifty day simple moving average of $7.52 and a 200 day simple moving average of $4.19.
Virios Therapeutics Company Profile
Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
Further Reading
- Five stocks we like better than Virios Therapeutics
- What is a Dividend King?
- Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell
- How to Use the MarketBeat Stock Screener
- Top 3 Beverage Stocks Pouring Out Profits
- Golden Cross Stocks: Pattern, Examples and Charts
- CarMax and Carvana: Steering the Used Car Market
Receive News & Ratings for Virios Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virios Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
